Clinical Trials on Upper Facial Lines (Glabellar Lines, Forehead Lines, & Lateral Canthal Lines)

Total 210 results

Revance Therapeutics, Inc.

Completed

Efficacy and Safety of DaxibotulinumtoxinA (DAXI) for Injection for Treatment of Upper Facial Lines

Upper Facial Lines (Glabellar Lines, Forehead Lines, & Lateral Canthal Lines)

United States, Canada
Merz Pharmaceuticals GmbH

Completed

Safety and Efficacy Study of the Simultaneous Treatment of Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines and Lateral Canthal Lines) in Subjects With Moderate to Severe Upper Facial Lines (ULTRA I)

Moderate to Severe Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines, and Lateral Canthal Lines)

United States
Merz Pharmaceuticals GmbH

Completed

Safety and Efficacy Study of the Simultaneous Treatment of Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines and Crows Feet) in Subjects With Moderate to Severe Upper Facial Lines. (ULTRA II)

Moderate to Severe Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines, and Lateral Canthal Lines)

Germany
Merz North America, Inc.

Terminated

Longitudinal Evaluation and Real-world Evidence of NT201

Glabellar Frown Lines and Canthal Lines and/or Horizontal Forehead Lines in the Upper Face

United States
Medy-Tox

Completed

MT10109L in the Long-term, Open-label Treatment of Glabellar Lines (GL) and Lateral Canthal Lines (LCL)

Lateral Canthal Lines | Glabellar Lines

United States, Russian Federation, Germany, Canada, Belgium, United Kingdom
Medy-Tox

Completed

MT10109L in the Treatment of Lateral Canthal Lines With or Without Concurrent Treatment of Glabellar Lines

Lateral Canthal Lines | Glabellar Lines

United States, Germany, Canada
Medy-Tox

Completed

MT10109L in the Treatment of Glabellar Lines (GL) With or Without Concurrent Treatment of Lateral Canthal Lines (LCL)

Lateral Canthal Lines | Glabellar Lines

United States, Germany, Canada, United Kingdom
Allergan

Completed

BOTOX® in the Treatment of Upper Facial Lines in Japan

Glabellar Lines | Frown Lines | Crow's Feet Lines | Upper Facial Rhytides

Japan
Galderma R&D

Completed

Long-term Treatment of Moderate to Severe Glabellar Lines and Lateral Canthal Lines (READY-4)

Lateral Canthal Lines | Glabellar Lines

United States, Puerto Rico
Galderma R&D

Completed

Treatment of Moderate to Severe Lateral Canthal Lines and Glabellar Lines Alone or in Combination (READY-3)

Glabellar Frown Lines (GL) | Lateral Canthal Lines (LCL)

United States, Canada
Galderma R&D

Completed

Assess Aesthetic Improvement With QM1114-DP in Subjects With Moderate to Severe Lateral Canthal Lines and Glabellar Lines

Glabellar Frown Lines | Canthal Lines

United States
Ipsen

Terminated

Study to Evaluate the Safety and Efficacy of IPN59011 in Improving the Appearance of Moderate to Severe Upper Facial Lines. (LONG-SET)

Moderate Upper Facial Lines | Severe Upper Facial Lines

Germany
Allergan

Completed

Safety and Effectiveness of BOTOX® for Lateral Canthal Lines With or Without Simultaneous Glabellar Lines in Korea

Lateral Canthal Lines | Crow's Feet Lines

Korea, Republic of
Allergan

Completed

BOTOX® in the Treatment of Crow's Feet Lines in China

Lateral Canthal Lines | Crow's Feet Lines

China
Allergan

Completed

Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines

Glabellar Lines | Crow's Feet Lines | Facial Rhytides

Germany, Canada, United States, France
Daewoong Pharmaceutical Co. LTD.

Unknown

Efficacy and Safety of DWP450 for Treating Crows Feet Lines(CFL) in Combination With Glabellar Lines(Extension Study)

Glabellar Lines | Crow's Feet Lines
Allergan

Completed

Patient Satisfaction Study of Combined Facial Treatment With BOTOX® Cosmetic, JUVÉDERM® and LATISSE® (HARMONY Study)

Glabellar Lines | Nasolabial Fold | Crow's Feet Lines | Facial Rhytides

United States
Allergan

Completed

A Study To Assess the Adverse Effects and Change in Condition of OnabotulinumtoxinA X Injection in Adult Participants With Forehead Lines

Forehead Lines

United States
Allergan

Completed

Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines

Glabellar Lines | Crow's Feet Lines | Facial Rhytides

Germany, Canada, United States, France
Daewoong Pharmaceutical Co. LTD.

Completed

Evaluate the Safety and Explore the Efficacy of DWP712 With Moderate to Severe Glabellar Lines

Glabellar Lines

Korea, Republic of
Allergan

Completed

A Study to Assess Adverse Events and Change in Disease Activity of Intramuscular AGN-151586 Injection in Toxin-Naïve Adult Participants With Glabellar Lines

Glabellar Lines

United States, Canada
Medy-Tox

Completed

MT10109L in the Treatment of Glabellar Lines

Glabellar Lines

United States, Belgium, Russian Federation
CKD Bio Corporation

Completed

Safety and Efficacy of CKDB-501A in Subjects With Moderate-to-severe Glabellar Lines

Glabellar Lines

Korea, Republic of
Ipsen

Completed

Dysport in the Treatment of Glabellar Lines in Chinese Subjects

Glabellar Lines

China
Allergan

Completed

Safety and Efficacy of Two Types of Botulinum Toxin Type A For the Treatment of Glabellar Lines

Glabellar Lines

Germany
Huons Co., Ltd.

Completed

The Safety and Efficacy Study of HU-014 Versus Botox® in Subject With Moderate to Severe Glabellar Lines

Glabellar Lines

Korea, Republic of
GlaxoSmithKline

Completed

A Study Of BOTOX For The Treatment Of Glabellar Lines

Glabellar Lines

China
Pacira CryoTech, Inc., a wholly owned subsidiary...

Completed

Study Evaluating the Treatment of Forehead and/or Glabellar Lines With the CRYO-TOUCH III Device

Glabellar Frown Lines | Frown Lines

United States
Pacira CryoTech, Inc., a wholly owned subsidiary...

Completed

A Prospective Study Evaluating the Treatment of Forehead and/or Glabellar Lines With the Cryo-Touch IV Device

Glabellar Frown Lines | Frown Lines

United States
Medy-Tox

Completed

MT10109L in the Treatment of Lateral Canthal Lines

Lateral Canthal Lines

United States, Russian Federation, United Kingdom
AbbVie

Active, not recruiting

A Study to Assess the Adverse Events and Effectiveness of BOTOX Injections for the Treatment of Moderate to Severe Forehead Lines in Chinese Adult Participants

Forehead Lines

China
ATGC Co., Ltd.

Recruiting

Study to Compare the Efficacy and Safety of ATGC-110 (Botulinum Toxin) With Xeomin® for the Treatment of Moderate to Severe Glabellar Frown Lines

Glabellar Frown Lines

Korea, Republic of
Medy-Tox

Completed

Safety and Efficacy Study of Botulinum Toxin Type A to Treat Glabellar Lines

Glabellar Frown Lines

Australia
Galderma R&D

Active, not recruiting

Assess Aesthetic Improvement and Onset of QM1114-DP in Subjects With Moderate to Severe Glabellar Lines

Glabellar Frown Lines

United States
Galderma R&D

Completed

Safety and Efficacy Study of Botulinum Toxin for the Treatment of Glabellar Frown Lines

Glabellar Frown Lines

United States
Galderma R&D

Completed

Subject Satisfaction With AbobutulinumtoxinA Treatment (DREAM)

Glabellar Frown Lines

United States
Revance Therapeutics, Inc.

Completed

Efficacy and Safety of DaxibotulinumtoxinA for Injection to Treat Moderate to Severe Glabellar Lines

Glabellar Frown Lines

United States
Revance Therapeutics, Inc.

Completed

Safety of Single and Repeat Treatments of DaxibotulinumtoxinA for Injection for Treatment of Moderate to Severe Glabellar Lines

Glabellar Frown Lines

United States, Canada
Medytox Korea

Completed

Study to Evaluate the Efficacy and Safety of MBA-P01 in Subjects With Glabellar Lines

Glabellar Frown Lines

Korea, Republic of
Protox Inc.

Completed

The Safety and Efficacy Study of PROTOXIN in Subjects With Moderate to Severe Glabellar Lines

Glabellar Frown Lines

Korea, Republic of
Medy-Tox

Completed

Long-term Safety and Efficacy of MEDITOXIN® in Treatment Glabellar Lines

Glabellar Frown Lines

Korea, Republic of
Medy-Tox

Completed

The Efficacy and Safety of CUNOX® in Patients With Moderate to Severe Glabellar Lines

Glabellar Frown Lines

Russian Federation
Huons Co., Ltd.

Unknown

The Safety and Efficacy Study of Hutox Versus Botox® in Subject With Moderate to Severe Glabellar Lines

Glabellar Frown Lines

Korea, Republic of
Jetema USA Inc.

Not yet recruiting

Clinical Trial to Evaluate the Safety and Efficacy of JTM201 to Treat Moderate or Severe Glabellar Lines

Glabellar Lines
Huons Biopharma

Not yet recruiting

To Evaluate HU-045 in the Treatment of Glabellar Lines(Phase III)

Glabellar Lines
CKD Bio Corporation

Completed

Efficacy and Safety of CKDB-501A in Subjects With Moderate-to-severe Glabellar Lines in Phase 3 Trial

Glabellar Lines

Korea, Republic of
Allergan

Completed

A Study to Assess Adverse Events of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar Lines

Glabellar Lines

United States, Puerto Rico
Allergan

Completed

A Study of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar Lines

Glabellar Lines

United States
AbbVie

Completed

A Study to Evaluate Sequential Administration of AGN-151586 and OnabotulinumtoxinA (BOTOX) Injections in Adult Participants for Treatment of Glabellar Lines

Glabellar Lines

United States
CKD Bio Corporation

Completed

Safety and Efficacy of CKDB-501B in Subjects With Moderate-to-severe Glabellar Lines

Glabellar Lines

Korea, Republic of

3

Subscribe